Skip to main content
Markets · Live
DJIA50,687.07▼ -1.21%S&P 5007,553.68▼ -0.74%Nasdaq26,853.98▼ -0.89%Nvidia—▼ TSMC—▼ Alphabet—▼ Bitcoin—▼ DJIA50,687.07▼ -1.21%S&P 5007,553.68▼ -0.74%Nasdaq26,853.98▼ -0.89%Nvidia—▼ TSMC—▼ Alphabet—▼ Bitcoin—▼
New York--:--
Chicago--:--
Denver--:--
Los Angeles--:--
Honolulu--:--
Anchorage--:--
Tokyo--:--
Berlin--:--
London--:--
UTC--:--

Breaking

BLOOMBERG MARKETS — Dimon Concerned Inflation May Be Sticky, Rates Go Up · Oct 6, 10:07 AM ET
STAT

STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial

The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.

Elaine Chen
By Elaine Chen· STAT News· Published · Photo: Alkermes

Rights: fair use excerpt

STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial
Reporting by Elaine ChenSource: STAT NewsPhoto: AlkermesUpdated October 6, 2026
PHOTO: ALKERMES

---

Elaine Chen · STAT News · Photo: Alkermes

Source & Credit

Reporting and photography credited as noted above. Originally published by STAT News.

Members only

Checking your membership…